CALANDO PHARMACEUTICALS INC has a total of 27 patent applications. Its first patent ever was published in 2003. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and macromolecular chemistry and polymers are EXICURE INC, NEMESIS BIOSCIENCE LTD and WEISS SAMUEL.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Japan | 3 | |
#5 | Australia | 2 | |
#6 | Brazil | 2 | |
#7 | Canada | 2 | |
#8 | China | 2 | |
#9 | Israel | 2 | |
#10 | Hong Kong | 1 | |
#11 | Republic of Korea | 1 | |
#12 | Taiwan | 1 |
# | Name | Total Patents |
---|---|---|
#1 | Davis Mark E | 20 |
#2 | Heidel Jeremy D | 17 |
#3 | Roosi John J | 8 |
#4 | Liu Joanna Yi-Ching | 4 |
#5 | Rossi John J | 2 |
#6 | Bellocq Nathalie C | 2 |
#7 | Gonzalez Hector | 2 |
#8 | Pun Suzie Hwang | 2 |
#9 | Mark E Davis | 2 |
#10 | Cheng Jianjun | 2 |
Publication | Filing date | Title |
---|---|---|
WO2012174224A2 | Methods for administering nucleic acid-based therapeutics | |
BRPI0911332A2 | compositions and use of epas1 inhibitors | |
WO2008002470A2 | Sirna sequences against brf1 | |
CN101184840A | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof | |
US2006263435A1 | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |